Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity

References

• Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225. doi:10.1042/BSR20150089.
   PubMed Web of Science ®Google Scholar
• Diamantis N, Banerji U. Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer. 2016;114(4):362–67. doi:10.1038/bjc.2015.435.
   PubMed Web of Science ®Google Scholar
• Parslow AC, Parakh S, Lee FT, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Biomedicines. 2016;4(3):E14. doi:10.3390/biomedicines4030014.
   PubMed Web of Science ®Google Scholar
• Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Chauhan SC. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel). 2018;11(2):E32. doi:10.3390/ph11020032.
   PubMedGoogle Scholar
• Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J. Antibody-drug conjugates: promising and efficient tools for targeted cancer therapy. J Cell Physiol. 2018;233(9):6441–57. doi:10.1002/jcp.26435.
   PubMed Web of Science ®Google Scholar
• Chalouni C, Doll S. Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res. 2018;37(1):20. doi:10.1186/s13046-017-0667-1.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4(4):458–65. doi:10.4161/mabs.20230.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. Future Oncol. 2017;13(27):2405–11. doi:10.2217/fon-2017-0263.
   PubMed Web of Science ®Google Scholar
• Fabbri A, Cencini E, Gozzetti A, Schiattone L, Bocchia M. Therapeutic use of brentuximab vedotin in CD30+ hematologic malignancies. Anticancer Agents Med Chem. 2017;17(7):886–95. doi:10.2174/1871520616666160902100506.
   PubMed Web of Science ®Google Scholar
• Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018;11:4583–90. doi:10.2147/OTT.S141053.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65. doi:10.1182/blood-2003-01-0039.
   PubMed Web of Science ®Google Scholar
• Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res. 2011;17(20):6428–36. doi:10.1158/1078-0432.CCR-11-0488.
   PubMed Web of Science ®Google Scholar
• Gualberto A. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs. 2012;21(2):205–16. doi:10.1517/13543784.2011.641532.
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888–97. doi:10.1158/1078-0432.CCR-09-2069.
   PubMed Web of Science ®Google Scholar
• Masuda S, Miyagawa S, Sougawa N, Sawa Y. CD30-targeting immunoconjugates and bystander effects. Nat Rev Clin Oncol. 2015;12(4):245–245. doi:10.1038/nrclinonc.2014.159-c1.
   Web of Science ®Google Scholar
• Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, et al. The European medicines agency review of brentuximab vedotin (adcetris) for the treatment of adult patients with relapsed or refractory CD30+ hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2016;21(1):102–09. doi:10.1634/theoncologist.2015-0276.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: New boxed warning and contraindication for adcetris (brentuximab vedotin). 2016 May 10. https://www.fda.gov/Drugs/DrugSafety/ucm287668.html.
   Google Scholar
• Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, Thomas SH, Forman SJ, Kane SE. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–84. doi:10.1158/1535-7163.MCT-15-0036.
   PubMed Web of Science ®Google Scholar
• Wong DJ, Hurvitz SA. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med. 2014;2(12):122. doi:10.3978/j.issn.2305-5839.2014.08.13.
   PubMedGoogle Scholar
• Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. Ann Pharmacother. 2014;48(11):1484–93. doi:10.1177/1060028014545354.
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res. 2002;62:3736–42.
   PubMed Web of Science ®Google Scholar
• Nath N, Godat B, Zimprich C, Dwight SJ, Corona C, McDougall M, Urh M. Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. J Immunol Methods. 2016;431:11–21. doi:10.1016/j.jim.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab. 2012;13(7):901–10. doi:10.2174/138920012802138598.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426–33. doi:10.1158/0008-5472.CAN-05-4489.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496–512. doi:10.18632/oncotarget.v6i26.
   PubMedGoogle Scholar
• Sahota S, Vahdat LT. Sacituzumab govitecan: an antibody-drug conjugate. Expert Opin Biol Ther. 2017;17(8):1027–31. doi:10.1080/14712598.2017.1331214.
   PubMed Web of Science ®Google Scholar
• Kaur R, Kaur G, Gill RK, Soni R, Bariwal J. Recent developments in tubulin polymerization inhibitors: an overview. Eur J Med Chem. 2014;87:89–124. doi:10.1016/j.ejmech.2014.09.051.
   PubMed Web of Science ®Google Scholar
• Chen H, Lin Z, Arnst KE, Miller DD, Li W. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22(8):E1281. doi:10.3390/molecules22081281.
   PubMed Web of Science ®Google Scholar
• Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. 2011;52(9):1641–54. doi:10.3109/10428194.2011.574761.
   PubMed Web of Science ®Google Scholar
• Gruss H-J, Herrmann F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Leuk Lymphoma. 1996;20(5–6):397–409. doi:10.3109/10428199609052421.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214–21. doi:10.1158/0008-5472.CAN-05-3973.
   PubMed Web of Science ®Google Scholar
• Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. Aaps J. 2014;16(5):994–1008. doi:10.1208/s12248-014-9618-3.
   PubMed Web of Science ®Google Scholar
• Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, Yi JH, Girish S, Dybdal N, Reynolds T. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013;273(2):298–313. doi:10.1016/j.taap.2013.09.003.
   PubMed Web of Science ®Google Scholar
• de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, et al. U.S. food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845–49. doi:10.1158/1078-0432.CCR-12-1803.
   PubMed Web of Science ®Google Scholar
• FDA Drug Approval Package: ADCETRIS (brentuximab vedotin), Pharmacology review(s). 2016 Jan 4. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000PharmR.pdf.
   Google Scholar
• Liu Y, Zhou F, Sang H, Ye H, Chen Q, Yao L, Ni P, Wang G, Zhang J. LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). J Pharm Biomed Anal. 2017;137:170–77. doi:10.1016/j.jpba.2017.01.011.
   PubMed Web of Science ®Google Scholar